The FDA has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program. This is an expanded access program.
Published results showed umbilical cord-derived platelet-rich plasma provided better short-term pain relief but similar ...
The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 ...
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers ...
Inflammation covertly rewires the bone marrow, enabling mutated stem cells to rise and setting the stage for future blood disease.
Figure 1: Immunomodulatory effects of simulated MSCs. MSCs utilize different molecular mechanisms to suppress (in most cases) or activate immune cells. Orange arrows: inhibition; Green arrows: ...
The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback